{
    "pmcid": "8597880",
    "qa_pairs": {
        "How does NIH-CoVnb-112's classification as a class 1 RBD-specific nanobody contribute to its therapeutic potential?": [
            "It suggests potential use in a cocktail with other nanobodies targeting different epitopes",
            "It indicates a higher binding affinity to the spike protein",
            "It implies a longer half-life in the bloodstream",
            "It ensures specificity to a single SARS-CoV-2 variant"
        ],
        "What advantage does nebulized delivery of NIH-CoVnb-112 offer in treating respiratory diseases like COVID-19?": [
            "Direct engagement with the virus in the respiratory tract",
            "Increased systemic circulation of the nanobody",
            "Enhanced immune response throughout the body",
            "Improved absorption through the gastrointestinal tract"
        ],
        "What is the primary target of the NIH-CoVnb-112 nanobody in the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD)",
            "The N-terminal domain (NTD)",
            "The S2 subunit",
            "The fusion peptide"
        ],
        "What is the significance of the overlap between NIH-CoVnb-112's epitope and the ACE2 binding site on the RBD?": [
            "It allows the nanobody to neutralize multiple SARS-CoV-2 variants",
            "It enhances the nanobody's ability to bind to host cells",
            "It increases the nanobody's resistance to degradation",
            "It improves the nanobody's solubility in nebulized form"
        ],
        "Which structural feature of NIH-CoVnb-112 is crucial for its broad neutralization capability against SARS-CoV-2?": [
            "The large contact surface area on the RBD",
            "The presence of a disulfide bond in the nanobody",
            "The glycosylation sites on the nanobody",
            "The hydrophobic core of the nanobody"
        ]
    }
}